Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.

Atherosclerosis - 1 Mar 1995

Ordovas J M, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park J S, Cole T, Schaefer E J

Abstract excerpt

Our purpose was to assess the effect of apolipoprotein (apo) E and apo A-IV isoform variation on low density lipoprotein (LDL) cholesterol lowering response to the HMG CoA reductase inhibitor, pravastatin. Plasma samples were obtained from participants (apo E, n = 97; apo A-IV, n = 144) in the PLAC-I (Pravastatin Limitation of Atherosclerosis in Coronary Arteries Study-1). The mean LDL cholesterol reduction in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to APOE gene

Share to Heterozygote

Share to Homozygote

Share to Hyperlipoproteinemia Type II

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 7605354
DOI: 10.1016/0021-9150(94)05439-p

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.PMID 7605354Read ↗

Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol.Semantic proximity Read ↗

Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events.Semantic proximity Read ↗

Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol.Semantic proximity Read ↗

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.Semantic proximity Read ↗

Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting.Semantic proximity Read ↗

Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).Semantic proximity Read ↗

The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.Semantic proximity Read ↗

ApoA-IV phenotype affects diet-induced plasma LDL cholesterol lowering.Semantic proximity Read ↗

Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol.Semantic proximity Read ↗

Effects of apolipoprotein E phenotype on serum cholesterol level and cholesterol response to diet therapy in patients with hypercholesterolemia.Semantic proximity Read ↗

Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy.Semantic proximity Read ↗

Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.